Vivani Medical Inc. (VANI)
NASDAQ: VANIHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VANI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $102.83M
- EPS (TTM)
- -$0.33
- Dividend yield
- None
- 52-week range
- 0.80 – 1.66
- Day range
- 1.10 – 1.16
- Volume / Avg
- 448.60K / 228.83K
- Beta
- —
- Shares outstanding
- 90.20M
52-week range
VANI stock today
Vivani Medical (VANI) closed at $1.14 on Nov 20, up 4.59% (+$0.05), versus the S&P 500's 3.70% decline. At this level, VANI sits in the middle of its 52-week range of $0.80 to $1.66: 31.4% below the high, set on Jul 9, 2026 and 42.5% above the low. VANI is down 7.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.6%.
Vivani Medical has posted a net loss over the last twelve months (EPS of -$0.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Vivani Medical
Company profileVivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Dr. Adam Mendelsohn Ph.D.
- Headquarters
- Alameda, CA
- Employees
- 42
- IPO year
- 2014
- Website
- vivani.com
Financial highlights
Full financialsIn fiscal 2025, Vivani Medical generated $0 in revenue, up 0.0% from fiscal 2024. Vivani Medical reported a net loss of $26.6 million, compared with a loss of $23.5 million a year earlier. Diluted earnings per share came in at -$0.43.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-26.61M | $-23.49M | $-25.65M | $-13.89M | $-12.77M |
| EPS (diluted) | $-0.43 | $-0.43 | $-0.50 | — | $-0.27 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$3.83+235.96%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.08 vs —
VANI news
All VANI news- Vivani Medical Announces Private Placement Equity FinancingGlobeNewswire
- Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight SubjectsGlobeNewswire
- Vivani's Q3 Loss Widens Mildly To $7 Mln; Data For GLP-1 Implant Expected Later This WeekNasdaqNVO, VANI, HEI.A
- Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Vivani Medical Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key GoalNasdaqABBV, AZN, CMMB, GMAB
Vivani Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STXSStereotaxis Inc. | 0.9422 | -6.71% | $95.03M | vs VANI |
| HSDTSolana Company Class A | 1.49 | -10.24% | $93.70M | vs VANI |
| FOCLEDAP TMS S.A. ADR | 2.61 | -7.45% | $123.25M | vs VANI |
| NRXSNeuraxis Inc. | 4.22 | -6.22% | $59.90M | vs VANI |
| HYPRHyperfine Inc. Class A | 0.5465 | +4.27% | $57.96M | vs VANI |
| OMOutset Medical Inc. | 2.81 | -3.44% | $53.03M | vs VANI |
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs VANI |
| ECORelectroCore Inc. | 4.42 | -8.87% | $40.78M | vs VANI |
Indexes, lists and sector
Vivani Medical stock FAQ
What is Vivani Medical's stock price today?
VANI last traded at $1.14 as of Nov 20, 4:00 PM EST, up 4.59% on the day. Prices are delayed at least 15 minutes.
Does Vivani Medical pay a dividend?
No. Vivani Medical does not currently pay a regular cash dividend.
Who is Vivani Medical's CEO?
Dr. Adam Mendelsohn Ph.D. is the chief executive officer of Vivani Medical Inc., which has about 42 employees.
Has VANI ever split its stock?
Yes. The most recent VANI stock split was a 1-for-3 split on Aug 19, 2022, one of 2 splits on record.
What is the VANI 52-week high?
The 52-week high for VANI is $1.66 and the 52-week low is $0.80. The stock is currently 31.4% below its high.